ACOG (Alpha Cognition) Short Interest

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Alpha Cognition's Short Interest

For the Biotechnology subindustry, Alpha Cognition's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpha Cognition's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Cognition's Short Interest distribution charts can be found below:

* The bar in red indicates where Alpha Cognition's Short Interest falls into.

Save Embed

;

Save Embed

;

Alpha Cognition Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (NAS:ACOG) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 - 750 West Pender Street, Vancouver, BC, CAN, V6C 2T8

Website

https://www.alphacognition.com

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.